New Insights into Metformin’s Mechanism for Managing Type 2 Diabetes

For over six decades, metformin has been a go-to medication for managing blood sugar levels in people with type 2 diabetes. However, its exact mechanism has puzzled scientists for a long time—until now.

A recent study has revealed that metformin may operate directly in the brain, suggesting possible new avenues for treatment approaches.

Researchers at Baylor College of Medicine, in 2025, pinpointed a specific brain pathway that the drug seems to target, alongside its known effects on various bodily processes.

“Traditionally, it’s been thought that metformin primarily reduces blood glucose by lowering glucose production in the liver. Some other studies have pointed to its role in the gut,” explained Makoto Fukuda, a pathophysiologist at Baylor. “So, we turned our attention to the brain, recognized as a pivotal regulator of overall glucose metabolism, to explore its contribution to metformin’s anti-diabetic effects.”

In a summary video, the findings of their research are presented; check it out below.

Pioneering work by parts of the same research team had already identified a brain protein called Rap1 that influences glucose metabolism, particularly in a region of the brain known as the ventromedial hypothalamus (VMH).

During the research in 2025, tests involving mice showcased metformin moving into the VMH, where it seems to help manage type 2 diabetes by effectively shutting down Rap1.

Notably, mice bred without Rap1 showed no response to metformin in addressing diabetes-like conditions, which indicates that this drug operates through a unique brain mechanism—different from others.

The research provided robust evidence supporting the idea that metformin engages with the brain.

The team also examined specific neurons affected by the drug. In the future, this could pave the way for more targeted therapies aimed directly at these neurons.

“We explored the involvement of different cells in the VMH in mediating the effects of metformin,” Fukuda mentioned. “Our findings indicate that SF1 neurons become activated upon administration of metformin, suggesting they play a direct role in the drug’s function.”

Metformin is known for its longevity and affordability. It aids in reducing glucose production in the liver while also enhancing the body’s insulin usage, thus helping to manage type 2 diabetes symptoms. Now, with insights into its brain-related mechanism, its potential reach seems to be broadening.

Of course, further human studies are necessary to validate these findings. If proven correct, they may help enhance metformin’s potency and effectiveness.

“These discoveries could lead to new diabetes treatments that specifically target this brain pathway,” Fukuda stated. Furthermore, metformin is known for various other health benefits, such as slowing brain aging. Research is planned to determine whether this Rap1 signaling in the brain contributes to these additional effects.

This research aligns with other intriguing studies showing that metformin can slow down brain aging and enhance lifespan. A deeper understanding of metformin’s intricacies might see its application expand in the future.

While metformin is generally regarded as safer compared to other diabetes treatments, it does come with side effects. Gastrointestinal issues such as nausea and diarrhea can impact up to 75 percent of users, and complications may arise for those with conditions like kidney impairment.

It’s also labeled as a gerotherapeutic agent, implying it can slow various aging processes in the body. Research indicates it can limit DNA damage and promote gene activity associated with longevity.

Previous studies have highlighted metformin’s capacity to mitigate brain wear and tear and potentially reduce long COVID risks.

A 2025 study regarding over 400 postmenopausal women compared the effects of metformin to another diabetes medication, sulfonylurea.

The results indicated that those taking metformin had a 30 percent lower risk of dying before 90 compared to those on sulfonylurea, showcasing the drug’s potential impact on aging.

Overall, understanding how metformin interacts within the body can guide healthcare providers on prescribing it beyond diabetes treatment, possibly enhancing its safety further.

“This discovery truly shifts our perspective on metformin,” noted Fukuda. “It’s not only functioning in the liver and the gut; it’s also active in the brain.”

Interestingly, while high concentrations are needed for liver and gut responses, the brain reacts to much lower amounts of the drug.

The research findings appear in Science Advances.